Model correction of diagnostic coding-based RSV incidence for children 0-4 years in the US.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
21 Jun 2024
Historique:
received: 28 05 2023
accepted: 04 06 2024
medline: 22 6 2024
pubmed: 22 6 2024
entrez: 21 6 2024
Statut: epublish

Résumé

Although administrative claims data have a high degree of completeness, not all medically attended Respiratory Syncytial Virus-associated lower respiratory tract infections (RSV-LRTIs) are tested or coded for their causative agent. We sought to determine the attribution of RSV to LRTI in claims data via modeling of temporal changes in LRTI rates against surveillance data. We estimated the weekly incidence of LRTI (inpatient, outpatient, and total) for children 0-4 years using 2011-2019 commercial insurance claims, stratified by HHS region, matched to the corresponding weekly NREVSS RSV and influenza positivity data for each region, and modelled against RSV, influenza positivity rates, and harmonic functions of time assuming negative binomial distribution. LRTI events attributable to RSV were estimated as predicted events from the full model minus predicted events with RSV positivity rate set to 0. Approximately 42% of predicted RSV cases were coded in claims data. Across all regions, the percentage of LRTI attributable to RSV were 15-43%, 10-31%, and 10-31% of inpatient, outpatient, and combined settings, respectively. However, when compared to coded inpatient RSV-LRTI, 9 of 10 regions had improbable corrected inpatient LRTI estimates (predicted RSV/coded RSV ratio < 1). Sensitivity analysis based on separate models for PCR and antigen-based positivity showed similar results. Underestimation based on coding in claims data may be addressed by NREVSS-based adjustment of claims-based RSV incidence. However, where setting-specific positivity rates is unavailable, we recommend modeling across settings to mirror NREVSS's positivity rates which are similarly aggregated, to avoid inaccurate adjustments.

Sections du résumé

BACKGROUND BACKGROUND
Although administrative claims data have a high degree of completeness, not all medically attended Respiratory Syncytial Virus-associated lower respiratory tract infections (RSV-LRTIs) are tested or coded for their causative agent. We sought to determine the attribution of RSV to LRTI in claims data via modeling of temporal changes in LRTI rates against surveillance data.
METHODS METHODS
We estimated the weekly incidence of LRTI (inpatient, outpatient, and total) for children 0-4 years using 2011-2019 commercial insurance claims, stratified by HHS region, matched to the corresponding weekly NREVSS RSV and influenza positivity data for each region, and modelled against RSV, influenza positivity rates, and harmonic functions of time assuming negative binomial distribution. LRTI events attributable to RSV were estimated as predicted events from the full model minus predicted events with RSV positivity rate set to 0.
RESULTS RESULTS
Approximately 42% of predicted RSV cases were coded in claims data. Across all regions, the percentage of LRTI attributable to RSV were 15-43%, 10-31%, and 10-31% of inpatient, outpatient, and combined settings, respectively. However, when compared to coded inpatient RSV-LRTI, 9 of 10 regions had improbable corrected inpatient LRTI estimates (predicted RSV/coded RSV ratio < 1). Sensitivity analysis based on separate models for PCR and antigen-based positivity showed similar results.
CONCLUSIONS CONCLUSIONS
Underestimation based on coding in claims data may be addressed by NREVSS-based adjustment of claims-based RSV incidence. However, where setting-specific positivity rates is unavailable, we recommend modeling across settings to mirror NREVSS's positivity rates which are similarly aggregated, to avoid inaccurate adjustments.

Identifiants

pubmed: 38907351
doi: 10.1186/s12879-024-09474-y
pii: 10.1186/s12879-024-09474-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

617

Informations de copyright

© 2024. The Author(s).

Références

Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519–30.
doi: 10.1542/pir.35.12.519 pubmed: 25452661 pmcid: 5029757
Singh AK, Jain A, Jain B, Singh KP, Dangi T, Mohan M, et al. Viral aetiology of acute lower respiratory tract illness in hospitalised paediatric patients of a tertiary hospital: one year prospective study. Ind J Med Microbiol. 2014;32(1):13–8.
doi: 10.4103/0255-0857.124288
Stempel HE, Martin ET, Kuypers J, Englund JA, Zerr DM. Multiple viral respiratory pathogens in children with bronchiolitis. Acta Paediatr (Oslo Norway: 1992). 2009;98(1):123–6.
doi: 10.1111/j.1651-2227.2008.01023.x
Miller EK, Gebretsadik T, Carroll KN, Dupont WD, Mohamed YA, Morin LL, et al. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J. 2013;32(9):950–5.
doi: 10.1097/INF.0b013e31829b7e43 pubmed: 23694832
Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and mortality Associated with respiratory Syncytial Virus Versus Influenza infection in hospitalized older adults. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2019;69(2):197–203.
doi: 10.1093/cid/ciy991
Atamna A, Babich T, Froimovici D, Yahav D, Sorek N, Ben-Zvi H, et al. Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: comparison with seasonal influenza. Int J Infect Dis. 2021;103:489–93.
doi: 10.1016/j.ijid.2020.11.185 pubmed: 33249288
Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus Seasonality - United States, 2014–2017. MMWR Morbidity Mortal Wkly Rep. 2018;67(2):71–6.
doi: 10.15585/mmwr.mm6702a4
Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet (London England). 2017;390(10098):946–58.
doi: 10.1016/S0140-6736(17)30938-8 pubmed: 28689664 pmcid: 5592248
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The Burden of respiratory syncytial virus infection in Young Children. N Engl J Med. 2009;360(6):588–98.
doi: 10.1056/NEJMoa0804877 pubmed: 19196675 pmcid: 4829966
Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated hospitalizations among children aged < 2 years in the United States, 2014-15. J Pediatr Infect Dis Soc. 2019.
Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2012;54(10):1427–36.
doi: 10.1093/cid/cis211
Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status. BMC Public Health. 2017;17(1):271.
doi: 10.1186/s12889-017-4177-z pubmed: 28320361 pmcid: 5359836
Tran PT, Nduaguba SO, Diaby V, Choi Y, Winterstein AG. RSV testing practice and positivity by patient demographics in the United States: integrated analyses of MarketScan and NREVSS databases. BMC Infect Dis. 2022;22(1):681.
doi: 10.1186/s12879-022-07659-x pubmed: 35941563 pmcid: 9360654
Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443.
doi: 10.1186/s12879-015-1218-z pubmed: 26497750 pmcid: 4618996
Goldstein E, Finelli L, O’Halloran A, Liu P, Karaca Z, Steiner CA, et al. Hospitalizations Associated with respiratory Syncytial Virus and Influenza in Children, Including Children diagnosed with asthma. Epidemiol (Cambridge Mass). 2019;30(6):918–26.
doi: 10.1097/EDE.0000000000001092
Goldstein M, Krilov LR, Fergie J, McLaurin KK, Wade SW, Diakun D, et al. Respiratory Syncytial Virus hospitalizations among U.S. Preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016. Am J Perinatol. 2018;35(14):1433–42.
doi: 10.1055/s-0038-1660466 pubmed: 29920638 pmcid: 6260117
Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade SW, et al. The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for respiratory Syncytial Virus Immunoprophylaxis on Preterm infants Born in the United States. Am J Perinatol. 2018;35(2):192–200.
doi: 10.1055/s-0037-1606352 pubmed: 28881376

Auteurs

Sabina O Nduaguba (SO)

Department of Pharmaceutical Systems and Policy, College of Pharmacy, West Virginia University, Morgantown, WV, USA.
West Virginia University Cancer Institute, Morgantown, WV, USA.
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225 Center Drive, PO Box 100496, Gainesville, Florida, FL, 32611, USA.

Phuong T Tran (PT)

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225 Center Drive, PO Box 100496, Gainesville, Florida, FL, 32611, USA.
Faculty of Pharmacy, HUTECH University, Ho Chi Minh City, Vietnam.

Almut G Winterstein (AG)

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225 Center Drive, PO Box 100496, Gainesville, Florida, FL, 32611, USA. almut@cop.ufl.edu.
Center for Drug Evaluation and Safety, University of Florida, Gainesville, FL, USA. almut@cop.ufl.edu.
Department of Epidemiology, College of Medicine and College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA. almut@cop.ufl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH